A hitherto unreported high incidence of zoledronic acid-induced acute phase reaction in patients with cancer treatment-induced bone loss

Ann Oncol. 2007 Jan;18(1):201-202. doi: 10.1093/annonc/mdl298. Epub 2006 Oct 4.

Authors

D Santini¹, B Vincenzi², M Caraglia³, G Tonini²

Affiliations

¹ Oncology, University Campus Bio-Medico, Via Emilio Longoni 69, 00155 Rome. Electronic address: d.santini@unicampus.it.
² Oncology, University Campus Bio-Medico, Via Emilio Longoni 69, 00155 Rome.
³ Experimental Oncology Department, Experimental Pharmacology Unit, National Cancer Institute Fondazione 'G. Pascale', Naples, Italy.

PMID: 17021272
DOI: 10.1093/annonc/mdl298

No abstract available

Publication types

Letter

MeSH terms

Acute-Phase Reaction / etiology*
Aromatase Inhibitors / adverse effects*
Bone Density Conservation Agents / adverse effects*
Breast Neoplasms / drug therapy*
Diphosphonates / adverse effects*
Humans
Imidazoles / adverse effects*
Incidence
Osteoporosis / chemically induced
Osteoporosis / drug therapy*
Zoledronic Acid

Substances

Aromatase Inhibitors
Bone Density Conservation Agents
Diphosphonates
Imidazoles
Zoledronic Acid